Trial Profile

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Recurrent/Metastatic Nasopharyngeal Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jan 2025 Results of secondary analysis of multicenter, single-arm, phase II study (KL-A167) published in the Cancer Immunology Immunotherapy
31 Dec 2024 According to Sichuan Kelun-Biotech Biopharmaceutical media release, Professor Shi Yuankai is the principal investigator of the trial.
31 Dec 2024 According to Sichuan Kelun-Biotech Biopharmaceutical media release, company has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand1(PD-L1)-directed innovative humanized monoclonal antibody (mAb) tagitanlimab (formerly KL-A167) for the treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC) who have failed after prior 2L+ chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com